Literature DB >> 18787

Inhibition of secretin release and pancreatic bicarbonate secretion by somatostatin infusion in man.

L E Hanssen, K F Hanssen, J Myren.   

Abstract

Five healthy students were investigated on two different days with or without a constant infusion of somatostatin (500 microgram/h) into an arm vein a fluoroscopically placed Lagerlöf tube was used for the collection of gastric and duodenal juice. After 30-min basal period, 40 ml 100 mmol/l HCl was infused into the midpart of the duodenum over 5 min through a thin catheter attached to the tube. Plasma immunoreactive secretin was measured by radioimmunoassay employing 125I-labelled synthetic secretin, antibody against synthetic secretin, and standards prepared from pure natural porcine secretin. Secretin levels without somatostatin infusion were 4.6+/-0.7 pmol/l (mean+/-S.E.M.) basally and rose to a peak of 21.8+/-6.2 pmol/l after duodenal acidification (p less than 0.05) and with somatostatin infusion were 4.4+/-0.4 pmol/l basally and rose to a peak of 6.7+/-1.7 pmol/l (n.s.) after duodenal acidification. Pancreatic bicarbonate output increased from 8.0+/-2.5 mumol/min (mean+/-S.E.M.) to 283+/-44 mumol/min without somatostatin infusion (p less than 0.05) and from 6.7+/-2.1 mumol/min to 70+/-13 mumol/min somatostatin (p less than 0.05). This study shows that somatostatin (500 microgram/h can inhibit the release of secretin and the pancreatic bicarbonate secretion after duodenal acidification in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18787     DOI: 10.3109/00365527709181678

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  7 in total

1.  Helicobacter pylori-induced gastritis may contribute to occurrence of postprandial symptomatic hypoglycemia.

Authors:  O Açbay; A F Celik; P Kadioğlu; S Göksel; S Gündoğdu
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

Review 2.  Radioimmunoassay of secretin. A critical review and current status.

Authors:  T M Chang; W Y Chey
Journal:  Dig Dis Sci       Date:  1980-07       Impact factor: 3.199

3.  Somatostatinoma--the most recently described pancreatic islet cell tumor.

Authors:  C Reynolds; R Pratt; C Chan-Yan; W Boyko; W MacDonald; N Schmidt; R Rudland
Journal:  West J Med       Date:  1985-03

4.  Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera.

Authors:  A Ruskoné; E René; J A Chayvialle; N Bonin; F Pignal; M Kremer; S Bonfils; J C Rambaud
Journal:  Dig Dis Sci       Date:  1982-05       Impact factor: 3.199

5.  Relationship between diseases of the pancreas and hyperplasia of Brunner's glands.

Authors:  M Stolte; H Schwabe; H Prestele
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1981

6.  Randomised double blind trial of somatostatin in the treatment of massive upper gastrointestinal haemorrhage.

Authors:  I Magnusson; T Ihre; C Johansson; U Seligson; S Törngren; K Uvnäs-Moberg
Journal:  Gut       Date:  1985-03       Impact factor: 23.059

7.  Effects of dietary vitamin E on growth performance as well as intestinal structure and function of channel catfish (Ictalurus punctatus, Rafinesque 1818).

Authors:  Min He; Kaiyu Wang; Xiaoxia Liang; Jing Fang; Yi Geng; Zhengli Chen; Haibo Pu; Yaodong Hu; Xue Li; Ling Liu
Journal:  Exp Ther Med       Date:  2017-10-12       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.